Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, posted on LinkedIn about a recent paper by Seong-Keun Yoo et al. published in Nature Medicine:
“Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data
Predicting whether a patient with cancer will benefit from immune checkpoint inhibitors (ICIs) without resorting to advanced genomic or immunologic assays is an important clinical need.
Interesting paper in Nature Medicine – evaluated SCORPIO, a machine learning system that utilizes routine blood tests (complete blood count and comprehensive metabolic profile) alongside clinical characteristics from 9,745 ICI-treated patients across 21 cancer types.”
Authors: Seong-Keun Yoo et al.
More posts featuring Vivek Subbiah.